Editing GSK plc (section)

==Venture arms==
SR One was established in 1985, by SmithKline Beecham to invest in new biotechnology companies and continued operating after GSK was formed; by 2003, GSK had formed another subsidiary, GSK Ventures, to out-license or start new companies around drug candidates that it did not intend to develop further.<ref name=JPE2003>{{cite journal |last1=Reaume |first1=Andrew |title=Is Corporate Venture Capital a Prescription for Success in the Pharmaceutical Industry? |journal=The Journal of Private Equity |date=1 January 2003 |volume=6 |issue=4 |pages=77–87 |jstor=43503355 |doi=10.3905/jpe.2003.320058 |s2cid=154182967}}</ref> {{As of|2003}}, SR One tended to invest only if the company aligned with GSK's business.<ref name=JPE2003/>

In September 2019, Avalon Ventures announced that it entered into a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK. This includes its [[transglutaminase 2]] (TG2) small molecule program for the treatment of [[celiac disease]].<ref>{{Cite web |last=Keown |first=Alex |date=11 September 2019 |title=GSK to Acquire Celiac-Focused Sitari Pharmaceuticals |url=https://www.biospace.com/article/gsk-snaps-up-celiac-focused-sitari-pharmaceuticals/ |url-status=live |archive-url=https://web.archive.org/web/20190922084101/https://www.biospace.com/article/gsk-snaps-up-celiac-focused-sitari-pharmaceuticals/ |archive-date=22 September 2019 |website=BioSpace}}</ref>